ASX:IVQ

Stock Analysis Report

Executive Summary

Invitrocue Limited provides healthcare bio-analytics solutions primarily in Australia, China, Hong Kong, and Germany.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Invitrocue's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IVQ

2.1%

AU Biotechs

-0.2%

AU Market


1 Year Return

-34.8%

IVQ

36.2%

AU Biotechs

10.5%

AU Market

Return vs Industry: IVQ underperformed the Australian Biotechs industry which returned 36.2% over the past year.

Return vs Market: IVQ underperformed the Australian Market which returned 10.5% over the past year.


Shareholder returns

IVQIndustryMarket
7 Day0%2.1%-0.2%
30 Day0%6.3%-1.4%
90 Day-7.7%12.7%-1.0%
1 Year-34.8%-34.8%37.8%36.2%16.9%10.5%
3 Year-14.3%-14.3%149.9%140.9%36.9%18.6%
5 Yearn/a226.2%205.2%50.2%16.2%

Price Volatility Vs. Market

How volatile is Invitrocue's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Invitrocue undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Invitrocue is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Invitrocue has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Invitrocue forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invitrocue has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Invitrocue performed over the past 5 years?

34.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IVQ is unprofitable, but has reduced losses over the past 5 years at a rate of 34.3% per year.

Accelerating Growth: Unable to compare IVQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.2%).


Return on Equity

High ROE: IVQ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: IVQ is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IVQ is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Invitrocue's financial position?


Financial Position Analysis

Short Term Liabilities: IVQ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IVQ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IVQ has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: IVQ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: IVQ has a high level of physical assets or inventory.

Debt Coverage by Assets: IVQ has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVQ has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IVQ has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.6% each year


Next Steps

Dividend

What is Invitrocue's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IVQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IVQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IVQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IVQ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Invitrocue's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Steven Fang 0

0yrs

Tenure

S$273,504

Compensation

Dr. Sing Boon Fang, also known as Steven, Ph.D., MBA, CIM (UK) founded Invitrocue Limited in March 2014 and also serves as its Managing Director and has been its Executive Director since March 2014. He has ...


CEO Compensation Analysis

Compensation vs. Market: Steven's total compensation ($USD187.69K) is about average for companies of similar size in the Australian market ($USD259.85K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.1yrs

Average Tenure

Experienced Management: IVQ's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

0.8yrs

Average Tenure

Experienced Board: IVQ's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyS$95622 Nov 18
Chow Yee Koh
EntityIndividual
Role
Secretary
Company Secretary
Shares12,000
Max PriceS$0.08

Ownership Breakdown


Management Team

  • Steven Fang

    Founder

    • Tenure: 0yrs
    • Compensation: S$273.50k
  • Sunny Tan

    Senior Vice President of Scientific Affairs & Business Development

    • Tenure: 2.1yrs
  • Chow Yee Koh

    Company Secretary

    • Tenure: 4.3yrs
    • Compensation: S$111.05k
  • Martin D. Bach

    Vice President of Operation

    • Tenure: 3.3yrs
  • Andreas Lindner

    CEO of Europe & Director

    • Tenure: 1.7yrs
    • Compensation: S$87.85k
  • Arial Yi

    Scientific Consultant

    • Tenure: 0.7yrs

Board Members

  • Steven Fang

    Founder

    • Tenure: 0yrs
    • Compensation: S$273.50k
  • Andreas Lindner

    CEO of Europe & Director

    • Tenure: 1.7yrs
    • Compensation: S$87.85k
  • Narayanan Iyer

    Chair of Medical Advisory Board

    • Tenure: 1yrs
  • David Waugh

    Clinical & Scientific Advisor

    • Tenure: 0.9yrs
  • Wee Chng

    Clinical Advisor

    • Tenure: 1.8yrs
  • Masakazu Toi

    Clinical Advisor

    • Tenure: 0yrs
  • Christian Peschel (69yo)

    Clinical Advisor

    • Tenure: 0.8yrs
  • Stefan Paepke

    Clinical Advisor

    • Tenure: 0.8yrs
  • Jesús Garcia-Foncillas

    Clinical Advisor

    • Tenure: 0.8yrs
  • Sharifuddin Bin Wahab

    Global Insurance Advisor

    • Tenure: 0.4yrs

Company Information

Invitrocue Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Invitrocue Limited
  • Ticker: IVQ
  • Exchange: ASX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$34.709m
  • Shares outstanding: 578.49m
  • Website: https://www.invitrocue.com

Location

  • Invitrocue Limited
  • 11 Biopolis Way
  • Helios No.12-07/08
  • Singapore
  • 138667
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVQASX (Australian Securities Exchange)Old Ordinary SharesAUAUDNo data
IVQASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2008
IVQCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2008

Biography

Invitrocue Limited provides healthcare bio-analytics solutions primarily in Australia, China, Hong Kong, and Germany. Its bio-analytics solutions include in vitro cell-based testing technologies and image  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 10:31
End of Day Share Price2019/08/08 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.